Sunitinib Malate, a Receptor Tyrosine Kinase Inhibitor, Is Effective in the Treatment of Restrictive Heart Failure due to Heart Metastases from Renal Cell Carcinoma

Publisher： Karger

E-ISSN： 1421-9751|114|1|67-71

ISSN： 0008-6312

Source： Cardiology, Vol.114, Iss.1, 2009-04, pp. : 67-71

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Heart Failure as First Sign of Development of Cardiac Metastases in a Patient with Diagnosis of Papillary Thyroid Carcinoma on Treatment with Tyrosine-Kinase Inhibitors: Differential Diagnoses and Clinical Management

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-08 ,pp. : 591-599

Karger

Access to resources Recommend Favorite

Life-Threatening Complications Associated with the Tyrosine Kinase Inhibitor Sunitinib Malate

By  

Urologia Internationalis, Vol. 85, Iss. 4, 2010-10 ,pp. : 475-478

Karger

Access to resources Recommend Favorite

Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study

By  

Oncology Research and Treatment, Vol. 36, Iss. 3, 2013-02 ,pp. : 95-100

Karger

Access to resources Recommend Favorite

Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor

By  

HISTOPATHOLOGY, Vol. 67, Iss. 6, 2015-12 ,pp. : 799-805

John Wiley & Sons Inc

Access to resources Recommend Favorite

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 17, Iss. 5, 2015-05 ,pp. : 510-517

John Wiley & Sons Inc

Access to resources Recommend Favorite